康缘药业：金振口服液等产品正加紧排产满足市场需求

Core Insights - The company has reported a recovery in market demand for its antiviral and flu products, specifically the Jin Zhen oral solution and Re Du Ning injection, in the fourth quarter [1] - Jin Zhen oral solution has shown high efficacy in treating mild pneumonia caused by Mycoplasma pneumoniae and has been effective in improving symptoms such as fever and cough [1] - The product has also demonstrated significant inhibitory effects on respiratory syncytial virus and influenza viruses, including H1N1 and H3N2, while improving lung tissue health and regulating immune function [1] Product Performance - Jin Zhen oral solution has been included in several clinical guidelines for the treatment of hand-foot-mouth disease, pediatric respiratory infections, and Mycoplasma pneumoniae pneumonia [2] - In 2024, the company reported total revenue of 3.898 billion yuan, with Jin Zhen oral solution sales increasing by 5.13%, contributing approximately 815 million yuan, which accounts for over 20% of total revenue [2] - For the first three quarters of the year, the company achieved total revenue of 2.343 billion yuan, with oral liquid products, led by Jin Zhen, generating 1.359 billion yuan, representing 58% of total sales [2]